Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatosis 2 × Doxycycline × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pleural Effusion, Malignant 4 Breast Neoplasms 4 Immunoglobulin Light-chain Amyloidosis 3 Carcinoma, Non-Small-Cell Lung 3 Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Mycosis Fungoides 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, Non-Hodgkin 2 Exanthema 2 Colorectal Neoplasms 2 Amyloidosis 2 Waldenstrom Macroglobulinemia 1 Urologic Neoplasms 1 Tuberous Sclerosis 1 Triple Negative Breast Neoplasms 1 Tissue Adhesions 1 Skin Toxicity 1 Sezary Syndrome 1 Ras-wildtype Colorectal Cancer 1 Polyps 1 Pleural Neoplasms 1 Pain 1 Ovarian Neoplasms 1 Neurofibromatosis 2 1 Neoplasms, Second Primary 1 Neoplasms 1 Myoma 1 Melanoma 1 Lymphoma, T-Cell 1

Interventions

Bevacizumab 5 Everolimus 4 Sirolimus 2 Lapatinib 2 temsirolimus 1 neratinib 1 icotinib 1 emvododstat 1 brolucizumab 1 brigatinib 1 aflibercept 1 Vascular Endothelial Growth Factor A 1 Valproic Acid 1 Sunitinib 1 Magnetic Resonance Imaging 1 Immunoglobulin G 1 HDAC-42 1 Exome 1 Endostatins 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Axitinib 1 Aspirin 1 AZD 6244 1 89Zr-bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05521048 2025-12-08

Doxycycline in Cutaneous Schwannoma (NF2)

Massachusetts Eye and Ear Infirmary

Phase 1/2 Active not recruiting

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡